{
  "zip": "2072",
  "sector": "Healthcare",
  "longBusinessSummary": "Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.",
  "city": "Gordon",
  "phone": "61 2 9144 2223",
  "state": "NSW",
  "country": "Australia",
  "companyOfficers": [],
  "website": "http://www.noxopharm.com",
  "maxAge": 1,
  "address1": "828 Pacific Highway",
  "industry": "Biotechnology",
  "address2": "Suite 3 Level 4",
  "previousClose": 0.35,
  "regularMarketOpen": 0.35,
  "twoHundredDayAverage": 0.19543478,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 0.35,
  "navPrice": null,
  "averageDailyVolume10Day": 0,
  "totalAssets": null,
  "regularMarketPreviousClose": 0.35,
  "fiftyDayAverage": 0.34,
  "trailingAnnualDividendRate": null,
  "open": 0.35,
  "averageVolume10days": 0,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.837701,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 0.35,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 5000,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 108251496,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 301,
  "priceToSalesTrailing12Months": null,
  "dayLow": 0.35,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 5000,
  "fiftyTwoWeekHigh": 0.45,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.084,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 0.35,
  "exchange": "PNK",
  "shortName": "NOXOPHARM LTD",
  "longName": "Noxopharm Limited",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "NOXOF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_346635783",
  "uuid": "40e4683e-6e54-3ffe-8b91-1b2379577c8e",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": -0.03265,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 256491008,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1593475200,
  "heldPercentInstitutions": 0,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.33312,
  "nextFiscalYearEnd": 1656547200,
  "mostRecentQuarter": 1593475200,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 145353309,
  "enterpriseValue": 74634200,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.35,
  "logo_url": "https://logo.clearbit.com/noxopharm.com"
}